Cargando…

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death

BACKGROUND: Dexrazoxane (DEX, ICRF-187) is the only clinically approved cardioprotectant against anthracycline cardiotoxicity. It has been traditionally postulated to undergo hydrolysis to iron-chelating agent ADR-925 and to prevent anthracycline-induced oxidative stress, progressive cardiomyocyte d...

Descripción completa

Detalles Bibliográficos
Autores principales: Popelová, O, Štěrba, M, Hašková, P, Šimůnek, T, Hroch, M, Gunčová, I, Nachtigal, P, Adamcová, M, Geršl, V, Mazurová, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736842/
https://www.ncbi.nlm.nih.gov/pubmed/19623174
http://dx.doi.org/10.1038/sj.bjc.6605192
_version_ 1782171367992459264
author Popelová, O
Štěrba, M
Hašková, P
Šimůnek, T
Hroch, M
Gunčová, I
Nachtigal, P
Adamcová, M
Geršl, V
Mazurová, Y
author_facet Popelová, O
Štěrba, M
Hašková, P
Šimůnek, T
Hroch, M
Gunčová, I
Nachtigal, P
Adamcová, M
Geršl, V
Mazurová, Y
author_sort Popelová, O
collection PubMed
description BACKGROUND: Dexrazoxane (DEX, ICRF-187) is the only clinically approved cardioprotectant against anthracycline cardiotoxicity. It has been traditionally postulated to undergo hydrolysis to iron-chelating agent ADR-925 and to prevent anthracycline-induced oxidative stress, progressive cardiomyocyte degeneration and subsequent non-programmed cell death. However, the additional capability of DEX to protect cardiomyocytes from apoptosis has remained unsubstantiated under clinically relevant in vivo conditions. METHODS: Chronic anthracycline cardiotoxicity was induced in rabbits by repeated daunorubicin (DAU) administrations (3 mg kg(−1) weekly for 10 weeks). Cardiomyocyte apoptosis was evaluated using TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick end labelling) assay and activities of caspases 3/7, 8, 9 and 12. Lipoperoxidation was assayed using HPLC determination of myocardial malondialdehyde and 4-hydroxynonenal immunodetection. RESULTS: Dexrazoxane (60 mg kg(−1)) co-treatment was capable of overcoming DAU-induced mortality, left ventricular dysfunction, profound structural damage of the myocardium and release of cardiac troponin T and I to circulation. Moreover, for the first time, it has been shown that DEX affords significant and nearly complete cardioprotection against anthracycline-induced apoptosis in vivo and effectively suppresses the complex apoptotic signalling triggered by DAU. In individual animals, the severity of apoptotic parameters significantly correlated with cardiac function. However, this effective cardioprotection occurred without a significant decrease in anthracycline-induced lipoperoxidation. CONCLUSION: This study identifies inhibition of apoptosis as an important target for effective cardioprotection against chronic anthracycline cardiotoxicity and suggests that lipoperoxidation-independent mechanisms are involved in the cardioprotective action of DEX.
format Text
id pubmed-2736842
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27368422010-09-01 Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death Popelová, O Štěrba, M Hašková, P Šimůnek, T Hroch, M Gunčová, I Nachtigal, P Adamcová, M Geršl, V Mazurová, Y Br J Cancer Translational Therapeutics BACKGROUND: Dexrazoxane (DEX, ICRF-187) is the only clinically approved cardioprotectant against anthracycline cardiotoxicity. It has been traditionally postulated to undergo hydrolysis to iron-chelating agent ADR-925 and to prevent anthracycline-induced oxidative stress, progressive cardiomyocyte degeneration and subsequent non-programmed cell death. However, the additional capability of DEX to protect cardiomyocytes from apoptosis has remained unsubstantiated under clinically relevant in vivo conditions. METHODS: Chronic anthracycline cardiotoxicity was induced in rabbits by repeated daunorubicin (DAU) administrations (3 mg kg(−1) weekly for 10 weeks). Cardiomyocyte apoptosis was evaluated using TUNEL (terminal deoxynucleotidyl transferase biotin-dUTP nick end labelling) assay and activities of caspases 3/7, 8, 9 and 12. Lipoperoxidation was assayed using HPLC determination of myocardial malondialdehyde and 4-hydroxynonenal immunodetection. RESULTS: Dexrazoxane (60 mg kg(−1)) co-treatment was capable of overcoming DAU-induced mortality, left ventricular dysfunction, profound structural damage of the myocardium and release of cardiac troponin T and I to circulation. Moreover, for the first time, it has been shown that DEX affords significant and nearly complete cardioprotection against anthracycline-induced apoptosis in vivo and effectively suppresses the complex apoptotic signalling triggered by DAU. In individual animals, the severity of apoptotic parameters significantly correlated with cardiac function. However, this effective cardioprotection occurred without a significant decrease in anthracycline-induced lipoperoxidation. CONCLUSION: This study identifies inhibition of apoptosis as an important target for effective cardioprotection against chronic anthracycline cardiotoxicity and suggests that lipoperoxidation-independent mechanisms are involved in the cardioprotective action of DEX. Nature Publishing Group 2009-09-01 2009-07-21 /pmc/articles/PMC2736842/ /pubmed/19623174 http://dx.doi.org/10.1038/sj.bjc.6605192 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Translational Therapeutics
Popelová, O
Štěrba, M
Hašková, P
Šimůnek, T
Hroch, M
Gunčová, I
Nachtigal, P
Adamcová, M
Geršl, V
Mazurová, Y
Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
title Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
title_full Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
title_fullStr Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
title_full_unstemmed Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
title_short Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
title_sort dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736842/
https://www.ncbi.nlm.nih.gov/pubmed/19623174
http://dx.doi.org/10.1038/sj.bjc.6605192
work_keys_str_mv AT popelovao dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath
AT sterbam dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath
AT haskovap dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath
AT simunekt dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath
AT hrochm dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath
AT guncovai dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath
AT nachtigalp dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath
AT adamcovam dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath
AT gerslv dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath
AT mazurovay dexrazoxaneaffordedprotectionagainstchronicanthracyclinecardiotoxicityinvivoeffectiverescueofcardiomyocytesfromapoptoticcelldeath